{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:55:00Z","timestamp":1777895700956,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ymgme.2021.09.007","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T16:17:15Z","timestamp":1632759435000},"page":"217-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagnostic challenges and disease management in patients with a mild Zellweger spectrum disorder phenotype"],"prefix":"10.1016","volume":"134","author":[{"given":"Gregory M.","family":"Enns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zineb","family":"Ammous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan W.","family":"Himes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janaina","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirish","family":"Palle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charina","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2021.09.007_bb0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2015.12.009","article-title":"Peroxisome biogenesis disorders in the Zellweger spectrum: an overview of current diagnosis, clinical manifestations, and treatment guidelines","volume":"117","author":"Braverman","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0010","first-page":"922","article-title":"Human disorders of peroxisome metabolism and biogenesis biochim","volume":"2016","author":"Waterham","year":"1863","journal-title":"Biophys. Acta"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fphys.2014.00307","article-title":"Peroxisome biogenesis in mammalian cells","volume":"5","author":"Fujiki","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s13353-017-0414-5","article-title":"Mild Zellweger syndrome due to a novel PEX6 mutation: correlation between clinical phenotype and in silico prediction of variant pathogenicity","volume":"58","author":"Rydzanicz","year":"2017","journal-title":"J. Appl. Genet."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0025","series-title":"GeneReviews\u00ae","article-title":"Zellweger spectrum disorder","author":"Steinberg","year":"2003"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.braindev.2018.07.015","article-title":"Atypical PEX16 peroxisome biogenesis disorder with mild biochemical disruptions and long survival","volume":"41","author":"Zaabi","year":"2019","journal-title":"Brain Dev"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0035","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1194\/jlr.R900009-JLR200","article-title":"Bile acids: the role of peroxisomes","volume":"50","author":"Ferdinandusse","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0040","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2174\/138920012803762747","article-title":"Peroxisomes, peroxisomal diseases, and the hepatotoxicity induced by peroxisomal metabolites","volume":"13","author":"Wanders","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0045","first-page":"151","article-title":"Zellweger spectrum disorders: clinical overview and management approach orphanet","volume":"10","author":"Klouwer","year":"2015","journal-title":"J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/cge.12170","article-title":"A deleterious mutation in the PEX2 gene causes Zellweger syndrome in individuals of Ashkenazi Jewish descent","volume":"85","author":"Fedick","year":"2014","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ymgme.2017.06.004","article-title":"Biochemical and genetic characterization of an unusual mild PEX3-related Zellweger spectrum disorder","volume":"121","author":"Bjorgo","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/humu.20833","article-title":"Genotype-phenotype correlation in PEX5-deficient peroxisome biogenesis defective cell lines","volume":"30","author":"Ebberink","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0065","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00415-016-8167-3","article-title":"Expanding the spectrum of PEX10-related peroxisomal biogenesis disorders: slowly progressive recessive ataxia","volume":"263","author":"Renaud","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0070","series-title":"Molecular Machines Involved in Peroxisome Biogenesis and Maintenance","first-page":"111","article-title":"Expanding the clinical phenotypes of peroxisome biogenesis disorders: PEX11 function in health and disease","author":"Kettelhut","year":"2014"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0075","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s11033-015-3885-7","article-title":"A novel mutation in the PEX12 gene causing a peroxisomal biogenesis disorder","volume":"42","author":"Konkol'ova","year":"2015","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0080","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1093\/hmg\/ddt238","article-title":"Functional analysis of PEX13 mutation in a Zellweger syndrome spectrum patient reveals novel homooligomerization of PEX13 and its role in human peroxisome biogenesis","volume":"22","author":"Krause","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0085","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/ped.12713","article-title":"First Japanese case of Zellweger syndrome with a mutation in PEX14","volume":"57","author":"Komatsuzaki","year":"2015","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0090","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pediatrneurol.2017.06.012","article-title":"Novel PEX26 mutation causing Zellweger syndrome presenting as feeding intolerance and hypotonia","volume":"75","author":"Stowe","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0095","first-page":"75","article-title":"Diagnosis of a mild peroxisomal phenotype with next-generation sequencing","volume":"9","author":"Ventura","year":"2016","journal-title":"Mol. Genet. Metabol. Rep."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0100","first-page":"46","article-title":"Expanding the spectrum of PEX16 mutations and novel insights into disease mechanisms","volume":"16","author":"Kumar","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1006\/mgme.1999.2926","article-title":"Genotype-phenotype correlations in disorders of peroxisome biogenesis","volume":"68","author":"Moser","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0110","series-title":"GeneReviews\u00ae","article-title":"Zellweger Spectrum Disorder","author":"Steinberg","year":"2017"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000490095","article-title":"Long-term cholic acid therapy in Zellweger spectrum disorders","volume":"12","author":"Heubi","year":"2018","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ddrr.1113","article-title":"Peroxisome biogenesis disorders: biological, clinical and pathophysiological perspectives","volume":"17","author":"Braverman","year":"2013","journal-title":"Dev. Disabil. Res. Rev"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0125","series-title":"Peroxisomes: Methods and Protocols","author":"Schrader","year":"2017"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/cge.13130","article-title":"Development and validation of a severity scoring system for Zellweger spectrum disorders","volume":"93","author":"Klouwer","year":"2018","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0135","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.braindev.2012.10.017","article-title":"Newly identified milder phenotype of peroxisome biogenesis disorder caused by mutated PEX3 gene","volume":"35","author":"Matsui","year":"2013","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10545-008-0969-8","article-title":"A PEX10 defect in a patient with no detectable defect in peroxisome assembly or metabolism in cultured fibroblasts","volume":"32","author":"Steinberg","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0145","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10545-016-9962-9","article-title":"Cholic acid therapy in zellweger spectrum disorders","volume":"39","author":"Berendse","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10545-015-9880-2","article-title":"Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthood","volume":"39","author":"Berendse","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/adc.59.3.222","article-title":"Patterns of Refsum's disease. Phytanic acid oxidase deficiency","volume":"59","author":"Poulos","year":"1984","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0160","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1172\/JCI118465","article-title":"Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal beta-oxidation defects","volume":"97","author":"Paton","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0165","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.bbamcr.2006.09.005","article-title":"Proteomics of the peroxisome","volume":"1763","author":"Saleem","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/3552e5c7-88d1-42c5-844d-4c2f2d722533","article-title":"The proteome of human liver peroxisomes: identification of five new peroxisomal constituents by a label-free quantitative proteomics survey","volume":"8","author":"Gronemeyer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijns2040015","article-title":"Newborn screening for X-linked adrenoleukodystrophy","volume":"2","author":"Moser","year":"2016","journal-title":"Int. J. Neonatal Screen"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cca.2012.12.005","article-title":"Analysis of a Chinese pedigree with Zellweger syndrome reveals a novel PEX1 mutation by next-generation sequencing","volume":"417","author":"Sun","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0185","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10545-008-0856-3","article-title":"Cerebral MRI as a valuable diagnostic tool in zellweger spectrum patients","volume":"31","author":"Weller","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1741-4520.2008.00201.x","article-title":"Effect of dietary Lorenzo's oil and docosahexaenoic acid treatment for zellweger syndrome","volume":"48","author":"Arai","year":"2008","journal-title":"Congenit. Anomal."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0195","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1167\/iovs.09-4020","article-title":"Visual follow-up in peroxisomal-disorder patients treated with docosahexaenoic acid ethyl ester","volume":"51","author":"Noguer","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0200","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0b013e3181f07061","article-title":"Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial","volume":"75","author":"Paker","year":"2010","journal-title":"Neurology"},{"issue":"suppl 2","key":"10.1016\/j.ymgme.2021.09.007_bb0205","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01811415","article-title":"Oral ether lipid therapy in patients with peroxisomal disorders","volume":"10","author":"Holmes","year":"1987","journal-title":"J. Inher. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0210","series-title":"CHOLBAM\u00ae (cholic acid) Capsules, for Oral Use [prescribing information]","author":"Manchester Pharmaceuticals Inc","year":"2020"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0215","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1159\/000494555","article-title":"Long-term cholic acid treatment in a patient with Zellweger spectrum disorder","volume":"12","author":"Heubi","year":"2018","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0220","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MPG.0000000000001657","article-title":"Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and zellweger spectrum disorders","volume":"65","author":"Heubi","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jimd.12042","article-title":"The cholic acid extension study in zellweger spectrum disorders: results and implications for therapy","volume":"42","author":"Klouwer","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0230","article-title":"Identification of a novel PEX14 mutation in Zellweger syndrome","volume":"2009","author":"Huybrechts","year":"2009","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0235","first-page":"956","article-title":"Hepatic dysfunction in peroxisomal disorders","volume":"2016","author":"Baes","year":"1863","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0240","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/ajmg.a.37628","article-title":"Normal cognitive outcome in a PEX6 deficient girl despite neonatal multisystem presentation","volume":"170","author":"Witters","year":"2016","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2021.09.007_bb0245","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1177\/0883073811435918","article-title":"Zellweger syndrome and associated brain malformations: report of a novel Peroxin1 (PEX1) mutation in a native American infant","volume":"27","author":"Mohebbi","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0250","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10545-017-0113-8","article-title":"Coagulopathy in zellweger spectrum disorders: a role for vitamin K","volume":"41","author":"Zeynelabidin","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0255","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0260","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tcm.2017.10.001","article-title":"Fabry disease: review and experience during newborn screening","volume":"28","author":"Hsu","year":"2018","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ymgme.2021.09.007_bb0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(07)60196-2","article-title":"Wilson's disease","volume":"369","author":"Ala","year":"2007","journal-title":"Lancet"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221007824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221007824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:50:57Z","timestamp":1761090657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221007824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1096719221007824"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.09.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic challenges and disease management in patients with a mild Zellweger spectrum disorder phenotype","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}